I have been involved in clinical research for novel therapeutics for both NF1-related neoplasms and for neuroblastoma. I was part of the team that did the work which led to the MEK inhibitor selumetinib gaining FDA approval. This was the first drug specifically approved for NF1-related plexiform neurofibroma therapy. I also led the nation NF Clinical Trials Consortium as Vice-Chair and still lead the Neurofibroma Committee within that consortium. I have also run multiple national clinical trials utilizing targeted inhibitors for high-risk neuroblastoma.
As Division Chief for Pediatric Hematology/Oncology/Stem Cell Transplant, my aim is to foster more bench to bedside trials by strengthening the connections between the laboratories and the clinicians here.
Fellowship - University of California at San Francisco, San Francisco, CA 07/1997-12/2000
Chief Residency - University of California at San Francisco, San Francisco, CA 07/1996-06/1997
Residency - University of California at San Francisco, San Francisco, CA 07/1993-6/1996
M.D. - Northwestern University, Evanston, IL 06/1993
